These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17570703)

  • 41. Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma.
    Ebinger M; Senf L; Wachowski O; Scheurlen W
    Pathol Oncol Res; 2004; 10(1):17-21. PubMed ID: 15029256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
    Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
    Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence.
    Marsit CJ; Kim DH; Liu M; Hinds PW; Wiencke JK; Nelson HH; Kelsey KT
    Int J Cancer; 2005 Mar; 114(2):219-23. PubMed ID: 15540210
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
    Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
    Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
    Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
    Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
    Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
    J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypermethylation of the RASSF1A gene in gliomas.
    Gao Y; Guan M; Su B; Liu W; Xu M; Lu Y
    Clin Chim Acta; 2004 Nov; 349(1-2):173-9. PubMed ID: 15469871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
    Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood.
    Mühlisch J; Schwering A; Grotzer M; Vince GH; Roggendorf W; Hagemann C; Sörensen N; Rickert CH; Osada N; Jürgens H; Frühwald MC
    Oncogene; 2006 Feb; 25(7):1111-7. PubMed ID: 16186793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
    Marini A; Mirmohammadsadegh A; Nambiar S; Gustrau A; Ruzicka T; Hengge UR
    J Invest Dermatol; 2006 Feb; 126(2):422-31. PubMed ID: 16374457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.
    Misawa A; Tanaka S; Yagyu S; Tsuchiya K; Iehara T; Sugimoto T; Hosoi H
    Br J Cancer; 2009 Jan; 100(2):399-404. PubMed ID: 19165202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aberrant methylation of multiple genes in neuroblastic tumours. relationship with MYCN amplification and allelic status at 1p.
    Gonzalez-Gomez P; Bello MJ; Lomas J; Arjona D; Alonso ME; Amiñoso C; Lopez-Marin I; Anselmo NP; Sarasa JL; Gutierrez M; Casartelli C; Rey JA
    Eur J Cancer; 2003 Jul; 39(10):1478-85. PubMed ID: 12826052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion.
    Katayama H; Hiraki A; Aoe K; Fujiwara K; Matsuo K; Maeda T; Murakami T; Toyooka S; Sugi K; Ueoka H; Tanimoto M
    Int J Cancer; 2007 May; 120(10):2191-5. PubMed ID: 17285579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
    Qiu GH; Tan LK; Loh KS; Lim CY; Srivastava G; Tsai ST; Tsao SW; Tao Q
    Oncogene; 2004 Jun; 23(27):4793-806. PubMed ID: 15122337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.
    Ohshima J; Haruta M; Fujiwara Y; Watanabe N; Arai Y; Ariga T; Okita H; Koshinaga T; Oue T; Hinotsu S; Nakadate H; Horie H; Fukuzawa M; Kaneko Y
    Pediatr Blood Cancer; 2012 Sep; 59(3):499-505. PubMed ID: 22457227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.
    House MG; Herman JG; Guo MZ; Hooker CM; Schulick RD; Lillemoe KD; Cameron JL; Hruban RH; Maitra A; Yeo CJ
    Ann Surg; 2003 Sep; 238(3):423-31; discussion 431-2. PubMed ID: 14501508
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carbon dioxide does not affect the methylation status of prognostic important oncogenes Rassf1A and DCR2 in neuroblastoma cells.
    Reismann M; Lehmann D; Quandte M; Ure BM; Glüer S
    Pediatr Surg Int; 2008 Dec; 24(12):1327-30. PubMed ID: 19002696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma.
    Morris MR; Hesson LB; Wagner KJ; Morgan NV; Astuti D; Lees RD; Cooper WN; Lee J; Gentle D; Macdonald F; Kishida T; Grundy R; Yao M; Latif F; Maher ER
    Oncogene; 2003 Oct; 22(43):6794-801. PubMed ID: 14555992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.